Arrowhead Pharmaceuticals (ARWR) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Arrowhead Pharmaceuticals (NASDAQ: ARWR) recently:

• 11/29/2024 – Arrowhead Pharmaceuticals had its price target lowered by analysts at Sanford C. Bernstein from $27.00 to $24.00. They now have a “market perform” rating on the stock.
• 11/27/2024 – Arrowhead Pharmaceuticals was upgraded by analysts at StockNews.com to a “sell” rating.
• 11/27/2024 – Arrowhead Pharmaceuticals had its price target lowered by analysts at Piper Sandler from $62.00 to $45.00. They now have an “overweight” rating on the stock.
• 11/27/2024 – Arrowhead Pharmaceuticals had its price target lowered by analysts at Citigroup Inc. from $27.00 to $26.00. They now have a “neutral” rating on the stock.
• 11/27/2024 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
• 11/20/2024 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
• 11/12/2024 – Arrowhead Pharmaceuticals was upgraded by analysts at StockNews.com to a “sell” rating.
• 10/17/2024 – Arrowhead Pharmaceuticals was upgraded by analysts at StockNews.com to a “sell” rating.
• 10/11/2024 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
• 10/8/2024 – Arrowhead Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $62.00 price target on the stock.

Arrowhead Pharmaceuticals Stock Up 1.2 %

ARWR stock opened at $26.34 on Tuesday. The firm has a market capitalization of $3.28 billion, a PE ratio of -5.25 and a beta of 0.90. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $17.05 and a twelve month high of $39.83. The stock has a 50-day simple moving average of $20.28 and a two-hundred day simple moving average of $23.23. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 2.06.

Institutional Trading of Arrowhead Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ARWR. Fifth Third Bancorp raised its position in shares of Arrowhead Pharmaceuticals by 42.5% during the second quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 354 shares during the last quarter. Values First Advisors Inc. bought a new stake in Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $52,000. Meeder Asset Management Inc. increased its holdings in Arrowhead Pharmaceuticals by 4,629.2% in the 2nd quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock worth $88,000 after acquiring an additional 3,333 shares during the last quarter. nVerses Capital LLC purchased a new stake in Arrowhead Pharmaceuticals in the second quarter valued at approximately $96,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Arrowhead Pharmaceuticals by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after buying an additional 788 shares during the period. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.